Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum.
作者信息
Yong Kok Pin, Kim Ho Jin
机构信息
Department of Neurology, National Neuroscience Institute, Singapore.
Duke-NUS Graduate Medical School, Singapore.
出版信息
Ann Transl Med. 2020 Jun;8(11):722. doi: 10.21037/atm.2020.01.119.
Abstract
摘要
相似文献
1
Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum.多发性硬化症中的疾病修饰疗法与感染风险——一个决策难题
Ann Transl Med. 2020 Jun;8(11):722. doi: 10.21037/atm.2020.01.119.
2
Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.多发性硬化症患者对疾病修正药物风险和益处的理解及偏好：一项系统综述。
J Neurol Sci. 2017 Apr 15;375:107-122. doi: 10.1016/j.jns.2016.12.038. Epub 2016 Dec 23.
3
Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment complexity.多发性硬化症的临床决策：随着治疗复杂性的增加，国际上报道的挑战。
Mult Scler Relat Disord. 2015 Jul;4(4):320-8. doi: 10.1016/j.msard.2015.05.008. Epub 2015 May 22.
4
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.从复发缓解型多发性硬化症患者的角度理解治疗决策：批判性综合解读。
Mult Scler Relat Disord. 2019 Jan;27:370-377. doi: 10.1016/j.msard.2018.11.016. Epub 2018 Nov 17.
5
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.权衡多发性硬化症患者疾病修正治疗的获益与风险。
J Neurol Sci. 2011 Dec;311 Suppl 1:S29-34. doi: 10.1016/S0022-510X(11)70006-5.
6
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.临床实践中口服与注射用多发性硬化症疾病修正治疗的疗效和耐受性
Mult Scler J Exp Transl Clin. 2016 Jan-Dec;2. doi: 10.1177/2055217316677868. Epub 2016 Nov 1.
7
Early Relapsing Multiple Sclerosis.早期复发型多发性硬化症
Continuum (Minneap Minn). 2016 Jun;22(3):744-60. doi: 10.1212/CON.0000000000000329.
8
Perception of risk and shared decision making process in multiple sclerosis.多发性硬化症中的风险认知与共同决策过程
Expert Rev Neurother. 2017 Feb;17(2):173-180. doi: 10.1080/14737175.2016.1217155. Epub 2016 Aug 4.
9
Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?在进展性多发性硬化症中停用疾病修正疗法：我们能否停止我们已经开始的治疗？
Mult Scler. 2009 Dec;15(12):1528-31. doi: 10.1177/1352458509351730. Epub 2009 Dec 7.
引用本文的文献
1
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.多发性硬化症患者感染新型冠状病毒肺炎的危险因素及临床结局：来自科索沃单一中心的回顾性研究
Med Sci Monit. 2024 Jan 30;30:e942992. doi: 10.12659/MSM.942992.
2
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.接受疾病修正治疗的多发性硬化症患者的感染风险：一项为期三年的观察性队列研究。
Mult Scler J Exp Transl Clin. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731. eCollection 2022 Jan-Mar.
3
Autoimmunity Increases Susceptibility to and Mortality from Sepsis.自身免疫会增加脓毒症的易感性和死亡率。
Immunohorizons. 2021 Oct 26;5(10):844-854. doi: 10.4049/immunohorizons.2100070.
4
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.在新冠疫情时代管理多发性硬化症：沙特阿拉伯专家小组对文献的回顾和共识报告。
Mult Scler Relat Disord. 2021 Jun;51:102925. doi: 10.1016/j.msard.2021.102925. Epub 2021 Mar 25.
本文引用的文献
1
High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis.韩国多发性硬化症患者中抗约翰·坎宁安病毒抗体的高血清阳性率及指数
J Clin Neurol. 2019 Oct;15(4):454-460. doi: 10.3988/jcn.2019.15.4.454.
2
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
3
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.实践指南更新概要：多发性硬化症中的疫苗可预防感染和免疫接种：美国神经病学学会指南制定、传播和实施小组委员会的报告。
Neurology. 2019 Sep 24;93(13):584-594. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.
4
Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?非延续性芬戈莫德-进行性多灶性白质脑病三例：日本的风险是否增加？
Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e559. doi: 10.1212/NXI.0000000000000559. eCollection 2019 May.
5
Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.淋巴细胞减少症与用于复发型多发性硬化症的疾病修正治疗药物：治疗神经科医生的考量
Neurol Clin Pract. 2019 Feb;9(1):53-63. doi: 10.1212/CPJ.0000000000000567.
6
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.免疫球蛋白水平、感染风险和死亡率与利妥昔单抗和低丙种球蛋白血症的关系。
JAMA Netw Open. 2018 Nov 2;1(7):e184169. doi: 10.1001/jamanetworkopen.2018.4169.
7
Treatment of multiple sclerosis - success from bench to bedside.多发性硬化症的治疗——从实验室到临床的成功。
Nat Rev Neurol. 2019 Jan;15(1):53-58. doi: 10.1038/s41582-018-0082-z.
8
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.利妥昔单抗诱导视神经脊髓炎谱系障碍患者出现低丙种球蛋白血症。
Neurol Neuroimmunol Neuroinflamm. 2018 Sep 13;5(6):e498. doi: 10.1212/NXI.0000000000000498. eCollection 2018 Nov.
9
High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis.中国多发性硬化症患者队列中抗约翰·坎宁安病毒抗体的高流行率及指标
Mult Scler J Exp Transl Clin. 2018 Jul 17;4(3):2055217318788699. doi: 10.1177/2055217318788699. eCollection 2018 Jul-Sep.
10
Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.多发性硬化症的疾病修正药物与感染风险：一项队列研究。
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30.
Zotero 插件